Novo Nordisk India and Emcure Pharma have announced a strategic partnership to commercialise Poviztra (semaglutide injection 2.4 mg) in India. The collaboration aims to strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.

With this agreement, Emcure Pharma becomes the first Indian company with exclusive rights to distribute and commercialise Poviztra, a second brand of Wegovy, in India.

Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025 and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight

See Full Page